View Future GrowthLavipharm 過去の業績過去 基準チェック /26Lavipharmは、平均年間29.5%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間8.5% 9.6%収益成長率で 成長しています。 Lavipharmの自己資本利益率は9.2%であり、純利益率は8%です。主要情報29.48%収益成長率-35.63%EPS成長率Pharmaceuticals 業界の成長7.33%収益成長率9.56%株主資本利益率9.18%ネット・マージン8.02%次回の業績アップデート17 Sep 2026最近の業績更新Reported Earnings • May 29First quarter 2026 earnings released: EPS: €0.005 (vs €0.005 in 1Q 2025)First quarter 2026 results: EPS: €0.005 (in line with 1Q 2025). Revenue: €14.7m (up 9.7% from 1Q 2025). Net income: €820.0k (down 2.7% from 1Q 2025). Profit margin: 5.6% (down from 6.3% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026お知らせ • Nov 01Lavipharm S.A. to Report Nine Months, 2024 Results on Nov 14, 2024Lavipharm S.A. announced that they will report nine months, 2024 results on Nov 14, 2024Reported Earnings • Sep 21Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €13.1m (down 16% from 2Q 2023). Net income: €6.63m (up 307% from 2Q 2023). Profit margin: 50% (up from 10% in 2Q 2023).お知らせ • Sep 02Lavipharm S.A. to Report First Half, 2024 Results on Sep 19, 2024Lavipharm S.A. announced that they will report first half, 2024 results on Sep 19, 2024Reported Earnings • May 29First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: €0.005. Revenue: €13.2m (down 4.6% from 1Q 2023). Net income: €780.0k (up 32% from 1Q 2023). Profit margin: 5.9% (up from 4.3% in 1Q 2023).すべての更新を表示Recent updatesDeclared Dividend • Jun 29Dividend of €0.02 announcedDividend of €0.02 is the same as last year. Ex-date: 20th July 2026 Payment date: 24th July 2026 Dividend yield will be 1.3%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is not covered by earnings (172% earnings payout ratio) nor is it covered by cash flows (167% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. The company's earnings per share (EPS) would need to grow by 92% to bring the payout ratio under control. However, EPS has declined by 26% over the last 5 years so the company would need to reverse this trend.お知らせ • Jun 27Lavipharm S.A. announces Annual dividend, payable on July 24, 2026Lavipharm S.A. announced Annual dividend of EUR 0.0200 per share payable on July 24, 2026, ex-date on July 20, 2026 and record date on July 21, 2026.Valuation Update With 7 Day Price Move • Jun 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €1.69, the stock trades at a trailing P/E ratio of 52.5x. Average trailing P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 192% over the past three years.New Risk • Jun 04New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 47% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (47% net debt to equity). Share price has been volatile over the past 3 months (10% average weekly change). Profit margins are more than 30% lower than last year (8.0% net profit margin).Reported Earnings • May 29First quarter 2026 earnings released: EPS: €0.005 (vs €0.005 in 1Q 2025)First quarter 2026 results: EPS: €0.005 (in line with 1Q 2025). Revenue: €14.7m (up 9.7% from 1Q 2025). Net income: €820.0k (down 2.7% from 1Q 2025). Profit margin: 5.6% (down from 6.3% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.Board Change • May 21Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Board Member Vasiliki Kefalas was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026お知らせ • Mar 15Lavipharm S.A., Annual General Meeting, Jul 03, 2025Lavipharm S.A., Annual General Meeting, Jul 03, 2025.お知らせ • Nov 01Lavipharm S.A. to Report Nine Months, 2024 Results on Nov 14, 2024Lavipharm S.A. announced that they will report nine months, 2024 results on Nov 14, 2024Reported Earnings • Sep 21Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €13.1m (down 16% from 2Q 2023). Net income: €6.63m (up 307% from 2Q 2023). Profit margin: 50% (up from 10% in 2Q 2023).お知らせ • Sep 02Lavipharm S.A. to Report First Half, 2024 Results on Sep 19, 2024Lavipharm S.A. announced that they will report first half, 2024 results on Sep 19, 2024Valuation Update With 7 Day Price Move • Jul 13Investor sentiment improves as stock rises 31%After last week's 31% share price gain to €1.02, the stock trades at a trailing P/E ratio of 71.9x. Average trailing P/E is 29x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 51% over the past year.Reported Earnings • May 29First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: €0.005. Revenue: €13.2m (down 4.6% from 1Q 2023). Net income: €780.0k (up 32% from 1Q 2023). Profit margin: 5.9% (up from 4.3% in 1Q 2023).お知らせ • May 01Lavipharm S.A. to Report Q1, 2024 Results on May 23, 2024Lavipharm S.A. announced that they will report Q1, 2024 results at 5:20 PM, GTB Standard Time on May 23, 2024New Risk • Apr 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €50.9m (up 11% from FY 2022). Net income: €2.00m (up 139% from FY 2022). Profit margin: 3.9% (up from 1.8% in FY 2022). The increase in margin was driven by higher revenue.お知らせ • Mar 01Lavipharm S.A. to Report Fiscal Year 2023 Results on Mar 21, 2024Lavipharm S.A. announced that they will report fiscal year 2023 results on Mar 21, 2024New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin).New Risk • Nov 10New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.5% Last year net profit margin: 2.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Minor Risk Profit margins are more than 30% lower than last year (0.5% net profit margin).お知らせ • Nov 01Lavipharm S.A. to Report Nine Months, 2023 Results on Nov 08, 2023Lavipharm S.A. announced that they will report nine months, 2023 results on Nov 08, 2023Board Change • Oct 19Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Board Member Vicky Kefalas was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 24Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €15.6m (up 52% from 2Q 2022). Net income: €1.63m (up 63% from 2Q 2022). Profit margin: 10% (in line with 2Q 2022).Board Change • Sep 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Board Member Vicky Kefalas was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 01Lavipharm S.A. to Report First Half, 2024 Results on Sep 21, 2023Lavipharm S.A. announced that they will report first half, 2024 results on Sep 21, 2023Board Change • May 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Mar 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 17First half 2022 earnings released: EPS: €0.037 (vs €0.15 in 1H 2021)First half 2022 results: EPS: €0.037 (down from €0.15 in 1H 2021). Revenue: €21.2m (up 8.4% from 1H 2021). Net income: €1.90m (down 27% from 1H 2021). Profit margin: 9.0% (down from 13% in 1H 2021). The decrease in margin was driven by higher expenses.Board Change • Aug 31Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.収支内訳Lavipharm の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:BXA0 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Mar 2665523031 Dec 2563523030 Sep 2555221130 Jun 2555221131 Mar 2552921131 Dec 2453921130 Sep 2446918030 Jun 2447819031 Mar 2452219031 Dec 2348218030 Sep 2354016130 Jun 2344116131 Mar 2349116131 Dec 2239115130 Sep 224324030 Jun 2241115131 Mar 2241112131 Dec 2140215130 Sep 2139215130 Jun 2139314131 Mar 2138214131 Dec 2038214130 Sep 2037414130 Jun 2036714131 Mar 2035614131 Dec 1934514130 Sep 1934314130 Jun 1934114131 Mar 1934115131 Dec 1834115130 Sep 1833016130 Jun 1832-116131 Mar 1832616131 Dec 17321315230 Sep 17321117230 Jun 17321018231 Mar 1732718231 Dec 1631418330 Sep 1631418330 Jun 1628415331 Mar 1627-215331 Dec 1526-715330 Sep 1527-9154質の高い収益: BXA0は 高品質の収益 を持っています。利益率の向上: BXA0の現在の純利益率 (8%)は、昨年(16.3%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: BXA0の収益は過去 5 年間で年間29.5%増加しました。成長の加速: BXA0は過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: BXA0は過去 1 年間で収益成長率がマイナス ( -39.7% ) となったため、 Pharmaceuticals業界平均 ( 15.6% ) と比較することが困難です。株主資本利益率高いROE: BXA0の 自己資本利益率 ( 9.2% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/13 07:34終値2026/07/10 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Lavipharm S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 29First quarter 2026 earnings released: EPS: €0.005 (vs €0.005 in 1Q 2025)First quarter 2026 results: EPS: €0.005 (in line with 1Q 2025). Revenue: €14.7m (up 9.7% from 1Q 2025). Net income: €820.0k (down 2.7% from 1Q 2025). Profit margin: 5.6% (down from 6.3% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026
お知らせ • Nov 01Lavipharm S.A. to Report Nine Months, 2024 Results on Nov 14, 2024Lavipharm S.A. announced that they will report nine months, 2024 results on Nov 14, 2024
Reported Earnings • Sep 21Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €13.1m (down 16% from 2Q 2023). Net income: €6.63m (up 307% from 2Q 2023). Profit margin: 50% (up from 10% in 2Q 2023).
お知らせ • Sep 02Lavipharm S.A. to Report First Half, 2024 Results on Sep 19, 2024Lavipharm S.A. announced that they will report first half, 2024 results on Sep 19, 2024
Reported Earnings • May 29First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: €0.005. Revenue: €13.2m (down 4.6% from 1Q 2023). Net income: €780.0k (up 32% from 1Q 2023). Profit margin: 5.9% (up from 4.3% in 1Q 2023).
Declared Dividend • Jun 29Dividend of €0.02 announcedDividend of €0.02 is the same as last year. Ex-date: 20th July 2026 Payment date: 24th July 2026 Dividend yield will be 1.3%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is not covered by earnings (172% earnings payout ratio) nor is it covered by cash flows (167% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. The company's earnings per share (EPS) would need to grow by 92% to bring the payout ratio under control. However, EPS has declined by 26% over the last 5 years so the company would need to reverse this trend.
お知らせ • Jun 27Lavipharm S.A. announces Annual dividend, payable on July 24, 2026Lavipharm S.A. announced Annual dividend of EUR 0.0200 per share payable on July 24, 2026, ex-date on July 20, 2026 and record date on July 21, 2026.
Valuation Update With 7 Day Price Move • Jun 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €1.69, the stock trades at a trailing P/E ratio of 52.5x. Average trailing P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 192% over the past three years.
New Risk • Jun 04New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 47% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (47% net debt to equity). Share price has been volatile over the past 3 months (10% average weekly change). Profit margins are more than 30% lower than last year (8.0% net profit margin).
Reported Earnings • May 29First quarter 2026 earnings released: EPS: €0.005 (vs €0.005 in 1Q 2025)First quarter 2026 results: EPS: €0.005 (in line with 1Q 2025). Revenue: €14.7m (up 9.7% from 1Q 2025). Net income: €820.0k (down 2.7% from 1Q 2025). Profit margin: 5.6% (down from 6.3% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • May 21Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Board Member Vasiliki Kefalas was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026
お知らせ • Mar 15Lavipharm S.A., Annual General Meeting, Jul 03, 2025Lavipharm S.A., Annual General Meeting, Jul 03, 2025.
お知らせ • Nov 01Lavipharm S.A. to Report Nine Months, 2024 Results on Nov 14, 2024Lavipharm S.A. announced that they will report nine months, 2024 results on Nov 14, 2024
Reported Earnings • Sep 21Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €13.1m (down 16% from 2Q 2023). Net income: €6.63m (up 307% from 2Q 2023). Profit margin: 50% (up from 10% in 2Q 2023).
お知らせ • Sep 02Lavipharm S.A. to Report First Half, 2024 Results on Sep 19, 2024Lavipharm S.A. announced that they will report first half, 2024 results on Sep 19, 2024
Valuation Update With 7 Day Price Move • Jul 13Investor sentiment improves as stock rises 31%After last week's 31% share price gain to €1.02, the stock trades at a trailing P/E ratio of 71.9x. Average trailing P/E is 29x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 51% over the past year.
Reported Earnings • May 29First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: €0.005. Revenue: €13.2m (down 4.6% from 1Q 2023). Net income: €780.0k (up 32% from 1Q 2023). Profit margin: 5.9% (up from 4.3% in 1Q 2023).
お知らせ • May 01Lavipharm S.A. to Report Q1, 2024 Results on May 23, 2024Lavipharm S.A. announced that they will report Q1, 2024 results at 5:20 PM, GTB Standard Time on May 23, 2024
New Risk • Apr 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €50.9m (up 11% from FY 2022). Net income: €2.00m (up 139% from FY 2022). Profit margin: 3.9% (up from 1.8% in FY 2022). The increase in margin was driven by higher revenue.
お知らせ • Mar 01Lavipharm S.A. to Report Fiscal Year 2023 Results on Mar 21, 2024Lavipharm S.A. announced that they will report fiscal year 2023 results on Mar 21, 2024
New Risk • Jan 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin).
New Risk • Nov 10New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.5% Last year net profit margin: 2.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Minor Risk Profit margins are more than 30% lower than last year (0.5% net profit margin).
お知らせ • Nov 01Lavipharm S.A. to Report Nine Months, 2023 Results on Nov 08, 2023Lavipharm S.A. announced that they will report nine months, 2023 results on Nov 08, 2023
Board Change • Oct 19Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Board Member Vicky Kefalas was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 24Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €15.6m (up 52% from 2Q 2022). Net income: €1.63m (up 63% from 2Q 2022). Profit margin: 10% (in line with 2Q 2022).
Board Change • Sep 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Board Member Vicky Kefalas was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 01Lavipharm S.A. to Report First Half, 2024 Results on Sep 21, 2023Lavipharm S.A. announced that they will report first half, 2024 results on Sep 21, 2023
Board Change • May 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Mar 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 17First half 2022 earnings released: EPS: €0.037 (vs €0.15 in 1H 2021)First half 2022 results: EPS: €0.037 (down from €0.15 in 1H 2021). Revenue: €21.2m (up 8.4% from 1H 2021). Net income: €1.90m (down 27% from 1H 2021). Profit margin: 9.0% (down from 13% in 1H 2021). The decrease in margin was driven by higher expenses.
Board Change • Aug 31Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.